Studies on the chemistry of technetium-99m radiopharmaceuticals

Narasimhan, D.; Vanaja, P.; Banodkar, S. M.; Mani, R. S.

doi:10.1007/bf02038188

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, TIBA was selected because it imparts similar X-ray attenuation properties to the FDA-approved, small-molecule triiodobenzoic acid derivative (Omnipaque 350, GE Healthcare) routinely used in clinical applications. To generate the multimodal character of the agent, the acyclic chelator, DTPA, was chosen to chelate tin(II)-reduced 99m Tc because of its established chemistry and stability. ,, Design of effective macromolecular, polymeric contrast agents for blood pool imaging requires long intravascular residence times. To further enhance the circulation half-life and limit clearance by the reticulo-endothelial system (RES), we chose to PEGylate the remainder of the surface with methoxy-terminated PEG.…”

Section: Discussionmentioning

confidence: 99%

Development and Application of a Multimodal Contrast Agent for SPECT/CT Hybrid Imaging

Criscione¹,

Dobrucki

Zhuang³

et al. 2011

Bioconjugate Chem.

View full text Add to dashboard Cite

Hybrid or multi-modality imaging is often applied, in order to take advantage of the unique and complementary strengths of individual imaging modalities. This hybrid non-invasive imaging approach can provide both critical information about anatomical structure in combination with physiological function or targeted molecular signals. While recent advances in software image fusion techniques and hybrid imaging systems have enabled efficient multimodal imaging, accessing the full potential of this technique requires development of a new toolbox of multimodal contrast agents that enhance the imaging process. Toward that goal, we report the development of a hybrid probe for both single photon emission computed tomography (SPECT) and X-ray computed tomography (CT) imaging that facilitates high sensitivity SPECT and high spatial resolution CT imaging. In this work, we report the synthesis and evaluation of a novel intravascular, multimodal dendrimer-based contrast agent for use in pre-clinical SPECT/CT hybrid imaging systems. This multimodal agent offers a long intravascular residence time (t1/2 = 43 min) and sufficient contrast-to-noise for effective serial intravascular and blood pool imaging with both SPECT and CT. The co-localization of the dendritic nuclear and X-ray contrasts offers the potential to facilitate image analysis and quantification by enabling correction for SPECT attenuation and partial volume errors at specified times with the higher resolution anatomic information provided by the circulating CT contrast. This may allow absolute quantification of intramyocardial blood volume and blood flow and may enable the ability to visualize active molecular targeting following clearance from the blood.

show abstract